Voyager Therapeutics IncVYGR
Price$2.68Intrinsic value$4.3763% above price

Valuation

How Intrinsic Value compares with model outputs

Intrinsic Value $4.37median of 2 methodsbased on filings through 30 Jun 2026
Market Price $2.68Price as of 30 Sep 2026
Margin of Safety +63.2%as of 30 Sep 2026

Valuation methods vs. Market Price

Company vs. peer median Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions

ParameterValue
Years 1–5: analyst growth pathFive-year total matches analyst consensus exactly. Year 1: 5.0% (near-term consensus, capped) · years 2–5: 18.0%/yr (balance of the path).15.3% per year
Years 6–10: glide to demonstrated growth
Per-year rates
Yr 617.4%Yr 716.9%Yr 816.3%Yr 915.8%Yr 1015.3%
18.0% → 15.3%
Years 11–20: glide to long-run rate
Per-year rates
Yr 1114.0%Yr 1212.8%Yr 1311.6%Yr 1410.4%Yr 159.1%Yr 167.9%Yr 176.7%Yr 185.5%Yr 194.2%Yr 203.0%
15.3% → 3.0%
Beyond year 20: terminal growthPerpetual long-run rate3.0%
Discount rate (cost of equity) 10.4%
Volatility vs market (adjusted beta)1.21

Valuation Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions Sandbox Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Compare with peers

Search any company to compare valuation, profitability, returns, growth, and financial strength side by side.

Compare the target company plus 1 peer. Sign in / Sign up to compare a maximum of 3 peers.

Best in rowHigher is betterLower is better—Data not available
TargetVoyager Therapeutics IncVYGRHealth Care
Valuation
P/E—
P/S5.5×
P/B1.2×
EV / Revenue5.5×
EV / EBITDA—
Profitability
Gross margin64.1%
Operating margin-1,167.6%
Net margin-312.6%
FCF margin-352.4%
Returns
ROE-69.8%
ROA-54.5%
ROIC—
Growth
Revenue growth (YoY)-56.9%
5-yr fwd EPS growth15.3%
Financial strength
Debt / Equity0.22×
Current ratio7.51×
Altman Z-Score-2.0
Interest coverage—
Dividend yield—

Best value in each row is highlighted. Figures are periodic snapshots from the same filings used across each dossier; a dash means the figure is not available.

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.